Stay updated on PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Sign up to get notified when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.

Latest updates to the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page
- ChecktodayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check29 days agoChange DetectedThe page has been updated to reflect new dates and details regarding the safety of combined drug therapy with radiation therapy, while previous information about toxicity rates and analysis has been removed.SummaryDifference7%
- Check36 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check44 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check58 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.3%
Stay in the know with updates to PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PROCEED Trial: Pembrolizumab Combo in Esophago-gastric Clinical Trial page.